News Releases

Friday, February 20, 2015

Survey shows postmenopausal women with VVA reported improved satisfaction and quality of life with VagiCapTM investigational local estrogen treatment

CLEVELAND – Newly released patient satisfaction survey results from a study of a novel investigational vaginal estrogen treatment show promise for improving quality of life and satisfaction for postmenopausal women who experience pain during sex and other symptoms associated with vulvar and vaginal atrophy (VVA).

University Hospitals Case Medical Center and TherapeuticsMD, Inc. (NYSE MKT: TXMD) announced that Sheryl A. Kingsberg, PhD, will present results today from a patient experience survey of investigational compound TX-004HR (VagiCapTM) at the International Society of Women’s Sexual Health (ISSWSH) 2015 Annual Meeting, February 19-22 at the Sheraton Hotel in Austin, Texas.

Dr. Kingsberg, Chief of the Division of Behavioral Medicine Department of OB/GYN at UH Case Medical Center in Cleveland, will present the findings of a survey evaluating use and satisfaction of a vaginal softgel capsule utilized in a pilot phase 2, 14-day study on VVA. The presentation, “Patient Experience with Solubilized Estradiol Given Vaginally in a Novel Softgel Capsule (VagiCapTM)” is scheduled for today at 11:40 a.m. CST. The ISSWSH Annual Meeting brings together scholars, researchers and practitioners to further their knowledge and commitment to the field of women’s sexual health.


Tuesday, February 10, 2015

Harrington Discovery Institute and The American Society for Clinical Investigation honor National Cancer Institute’s researcher Douglas R. Lowy, MD

CLEVELAND – The second annual Harrington Prize for Innovation in Medicine has been awarded to oncologist, researcher Douglas R. Lowy, MD, Chief, Laboratory of Cellular Oncology, and Deputy Director of the National Cancer Institute.  
 
The Harrington Prize for Innovation in Medicine, established in 2014 by the Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio and The American Society for Clinical Investigation (ASCI), honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and potential for clinical application.
 
Dr. Lowy is being recognized for his key discoveries that led to development of the human papillomavirus (HPV) vaccine to prevent cancer. The vaccine developed by Dr. Lowy (in collaboration with Merck and GlaxoSmithKline), and approved by the FDA in 2006, was the first licensed vaccine to prevent cancer by guarding against the sexually transmitted infection that causes the disease. It is estimated that the HPV vaccine can afford close to 100% protection and thus Dr. Lowy’s research has the potential to prevent virtually all of the many cancers caused by HPV.


Wednesday, January 28, 2015

University Hospitals appoints Marco Costa, MD, PhD, as new VP and Chief Innovation Officer

CLEVELAND – Manifesting its commitment to innovation, University Hospitals has created the Executive Office of Innovation and named Marco A. Costa, MD, PhD, as the new Vice President and Chief Innovation Officer of the health system.
 
In this new role, Dr. Costa will lead a team focused on initiatives related to innovation to maximize quality, patient experience and performance.
 
“Innovation in health care is an ongoing journey for all of us,” says Dr. Costa. “The current state of change in the health care environment provides many opportunities to be more pioneering with our roles in providing the highest-quality care and most personalized experiences for our patients.”


Wednesday, January 21, 2015

UH Case Medical Center first to offer novel HeartFlow FFRCT technology

CLEVELAND – Medical tests are stressful. Invasive tests, stress tests and unnecessary surgeries are too, not to mention the costs associated with all of them, but the alternative of undiagnosed heart problems are not. They can be fatal.   
 
UH Case Medical Center is now offering a new, non-invasive test for coronary artery disease designed to help physicians develop the right treatment plan for each patient. Developed by HeartFlow Inc., FFRCT  is the first and only non-invasive imaging technology specifically designed to offer insight on both the extent of the blockage, as well as whether it is impacting blood flow to the heart.
 
UH Case Medical Center’s Daniel Simon, MD, and Hiram Bezerra, MD, PhD were the first to use the FFRCT test in the United States on January 16. 


Tuesday, January 13, 2015

Advanced Biological Laboratories signs agreement with UH Case Medical Center to offer HIV drug resistance tests

CLEVELAND — University Hospitals (UH) Case Medical Center has signed an agreement with Advanced Biological Laboratories (ABL), an information technology and diagnostic company based in Luxembourg, to join efforts on the designing and validation of an HIV drug resistance and tropism assay based on next-generation sequencing (NGS).
 
Under the agreement, UH will begin using ABL’s DeepChek® analysis software with DEEPGEN™HIV, the HIV diagnostic test invented at University Hospitals’ Translational Laboratory by Miguel Quinones-Mateu, PhD, Scientific Director at the UH lab and Assistant Professor at the Department of Pathology, Case Western Reserve University School of Medicine. The new test will be offered as “DEEPGEN™HIV, powered by DeepChek®.”
 
The combined DEEPGEN™HIV/ DeepChek® test will aid monitoring the success of anti-HIV treatment by determining drug resistance and the ability of the virus to infect different cells based on deep genetic sequencing.  It will also provide a sensitive platform for HIV physicians and researchers, both in the academia and industry, to detect minority variants at frequencies unimaginable with standard HIV genotypic tests based on Sanger (population) sequencing.



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.